A
Alexandra Kemmer-Brück
Publications - 7
Citations - 2812
Alexandra Kemmer-Brück is an academic researcher. The author has contributed to research in topics: T cell & Immune system. The author has an hindex of 6, co-authored 7 publications receiving 1222 citations.
Papers
More filters
Journal ArticleDOI
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more
TL;DR: The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Journal ArticleDOI
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf,Sabrina Kuttruff-Coqui,Katrin Frenzel,Valesca Bukur,Stefan Stevanovic,Stefan Stevanovic,Cécile Gouttefangeas,Cécile Gouttefangeas,Michael Platten,Michael Platten,Ghazaleh Tabatabai,Ghazaleh Tabatabai,Valérie Dutoit,Sjoerd H. van der Burg,Per thor Straten,Per thor Straten,Francisco Martínez-Ricarte,Berta Ponsati,Hideho Okada,Ulrik Lassen,Arie Admon,Christian H. Ottensmeier,Alexander Ulges,Sebastian Kreiter,Andreas von Deimling,Andreas von Deimling,Marco Skardelly,Denis Migliorini,Judith R. Kroep,Manja Idorn,Manja Idorn,Jordi Rodon,Jordi Rodon,Jordi Piro,Hans Skovgaard Poulsen,Bracha Shraibman,Katy J. McCann,Regina Mendrzyk,Martin Löwer,Monika Stieglbauer,Cedrik M. Britten,David Capper,David Capper,David Capper,Marij J. P. Welters,Juan Sahuquillo,Katharina Kiesel,Evelyna Derhovanessian,Elisa Rusch,Lukas Bunse,Lukas Bunse,Colette Song,Sandra Heesch,Claudia Wagner,Alexandra Kemmer-Brück,Jorg Ludwig,John C. Castle,Oliver Schoor,Arbel D. Tadmor,Edward W. Green,Jens Fritsche,Miriam Meyer,Nina Pawlowski,Sonja Dorner,Franziska Hoffgaard,Bernhard Rossler,Dominik Maurer,Toni Weinschenk,Carsten Reinhardt,Christoph Huber,Hans-Georg Rammensee,Hans-Georg Rammensee,Harpreet Singh-Jasuja,Ugur Sahin,Pierre-Yves Dietrich,Wolfgang Wick,Wolfgang Wick +76 more
TL;DR: In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.
Journal ArticleDOI
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Ugur Sahin,Alexander Muik,Isabel Vogler,Evelyna Derhovanessian,Lena M. Kranz,Mathias Vormehr,Jasmin Quandt,Nicole Bidmon,Alexander Ulges,Alina Baum,Kristen E. Pascal,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Peter Koch,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Manuel Tonigold,Carsten Boesler,Corinna Rosenbaum,Ludwig Heesen,Marie Cristine Kühnle,Asaf Poran,Jesse Z. Dong,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Tania Palanche,Armin Schultz,Sybille Baumann,Azita J. Mahiny,Gábor Boros,Jonas Reinholz,Gábor Szabó,Katalin Karikó,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Mark Cutler,David A. Cooper,Christos A. Kyratsous,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +48 more
TL;DR: BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavalirus disease-19 (COVID-19)1 as mentioned in this paper.
Journal ArticleDOI
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Ugur Sahin,Petra Oehm,Evelyna Derhovanessian,Robert A. Jabulowsky,Mathias Vormehr,Maike Gold,Daniel Maurus,Doreen Schwarck-Kokarakis,Andreas Kuhn,Tana Omokoko,Lena M. Kranz,Mustafa Diken,Sebastian Kreiter,Heinrich Haas,Sebastian Attig,Richard Rae,Katarina Cuk,Alexandra Kemmer-Brück,Andrea Breitkreuz,Claudia Tolliver,Janina Caspar,Juliane Quinkhardt,Lisa Hebich,Malte Stein,Alexander Hohberger,Isabel Vogler,Inga Liebig,Stephanie Renken,Julian Sikorski,Melanie Leierer,Verena Müller,Heidrun Mitzel-Rink,Matthias Miederer,Christoph Huber,Stephan Grabbe,Jochen Utikal,Andreas Pinter,Roland Kaufmann,Jessica C. Hassel,Carmen Loquai,Özlem Türeci +40 more
TL;DR: Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4 + and CD8 + T-cell immunity.
Journal ArticleDOI
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more